BLISS GVS PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/05/2024 ,inter alia, to consider and approve a) To consider and approve the Audited Standalone and Consolidated Financial Results of the Company for the quarter and year ended March 31, 2024, along with the Statement of Assets and Liabilities, Cash Flow Statement and take note of the Audit Report with modified opinion, if any, thereon; b) To consider and approve the Audited Standalone and Consolidated Financial Statement of the Company for the financial year ended March 31, 2024; and c) To discuss and recommend the Final Dividend, if any, for the financial year ended March 31, 2024.